TriCalm Firm Appeals For Relief From NAD Decision On Itch Claims
This article was originally published in The Tan Sheet
Executive Summary
“NAD has shown it believes its opinion of what is scientifically appropriate (despite having no bona fides in the area) trumps that of accomplished medical professionals,” Cosmederm Bioscience argues. NAD rejects the firm’s support for all TriCalm ad claims challenged by Cortisone-10 marketer Chattem.